TargetMol

Femoxetine

Product Code:
 
TAR-T68069
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T68069-1mg1mg£239.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-5mg5mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-10mg10mg£686.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-25mg25mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-50mg50mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-100mg100mg£1,797.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68069-500mg500mg£3,516.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.
CAS:
59859-58-4
Formula:
C20H25NO2
Molecular Weight:
311.42
Pathway:
GPCR/G Protein|Metabolism|Neuroscience
Purity:
0.9906
SMILES:
C(OC1=CC=C(OC)C=C1)[C@@H]2[C@H](CCN(C)C2)C3=CC=CC=C3
Target:
5-HT Receptor|MAO

References

Dalsgaard-Nielsen J, et al. Changes in platelet function and blood serotonin level in migraine patients during treatment with femoxetine. Acta Neurol Scand. 1982;66(2):191-198. Warrington SJ, et al. Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men. Br J Clin Pharmacol. 1989;27(3):343-35 Schmidt J, et al. Femoxetine and cimetidine: interaction in healthy volunteers. Eur J Clin Pharmacol. 1986;31(3):299-30